This double-blind, placebo-controlled crossover trial (n=30) investigated the effects of MDMA compared to placebo on feelings of closeness and mood in semi-structured dyadic conversations.
Status: Completed
Start date: 2021-08-01
Phase I
Blinded
30 participants
Interventional
This open-label, phase 2 trial (n=18) will investigate the safety and preliminary effectiveness of MDMA-assisted therapy (MDMA-AT) in military veterans with co-occurring Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD).
Status: Not yet recruiting
Start date: 2023-09-01
Phase II
Open
18 participants
Interventional
This randomized, double-blind, placebo-controlled trial (n=80) will study the effects of repeated microdoses of lysergic acid diethylamide (LSD) on creativity and brain activity in healthy adult males. Participants will receive either 10 µg of LSD or a placebo, dissolved in water in 1 ml oral syringes, taken once every three days for a total of 14 doses over a 41-day regimen.
Status: Completed
Start date: 2019-11-19
Phase I
Blinded
80 participants
Interventional
This adaptive-design, phase IIa/IIb trial (n=70) aims to assess the safety, cardiovascular effects, pharmacokinetics, and pharmacodynamic profile of MSP-1014.OX (psilocin pro-drug) in patients with major depressive disorder (MDD) who have not responded adequately to SSRIs.
Status: Recruiting
Start date: 2023-06-28
Phase I
Blinded
70 participants
Interventional
This interventional trial (n=60) will assess the efficacy and safety of Psilocybin-Assisted Psychotherapy (PAP/PAT) involving family members in adults with treatment-resistant major depressive disorder (TRMDD). The study will compare two groups, one where PAT involves family members and another where PAT is conducted solely with therapists.
Status: Not yet recruiting
Start date: 2023-09-04
Phase I
Open
60 participants
Interventional
This randomized, double-blind, active-placebo controlled trial (n=60) will evaluate the effects of LSD on psychosocial distress in patients suffering from an end-stage fatal disease with a life expectancy of 12 weeks to 2 years.
Status: Not yet recruiting
Start date: 2023-09-01
Phase II
Blinded
60 participants
Interventional
This Phase I clinical trial (n=100) will assess the safety, pharmacokinetics, psychometric functions, and markers of brain activity and synaptic plasticity of DLX-001, a non-hallucinogenic psychoplastogen developed by Delix Therapeutics.
Status: Planned
Start date: 2023-05-19
Phase I
Open
100 participants
Interventional
This phase I/II trial (n=56) will study the safety and side effects of psilocybin in combination with therapy for treating cancer-related anxiety in patients with metastatic cancer. Psilocybin is being studied to treat anxiety or depression in patients with advanced cancer. Participants will receive psilocybin orally and participate in group and individual therapy sessions.
Status: Not yet recruiting
Start date: 2023-09-01
Phase I
Blinded
56 participants
Interventional
This trial is registered with the Dutch trial registry that has been offline for over a year and hasn't been registered in any other database. We will update this record once it becomes available. All data are estimates.
Status: Completed
Start date: 2022-01-01
Not Applicable
Open
22 participants
Interventional
This Phase I open-label trial (n=14) studied the safety of psilocybin when administered to healthy participants enrolled in a psychedelic-assisted therapy training program. Participants ingested 25 mg of psilocybin extract, and vital signs, including heart rate, blood pressure, temperature, and ECG, were monitored throughout the study.
Status: Completed
Start date: 2021-10-01
Phase I
Open
14 participants
Interventional
This open-label, single-arm Phase II clinical trial (n=15) will study the effects of GH001 (5-MEO-DMT) on patients with bipolar II disorder experiencing a major depressive episode.
Status: Recruiting
Start date: 2023-04-06
Phase II
Open
15 participants
Interventional
This randomized, interventional trial (n=30) will evaluate clinical outcomes, assess implementation feasibility, and health economics of MDMA-assisted therapy in the treatment of posttraumatic stress disorder (PTSD) in partnership with the Veterans Affairs (VA) Palo Alto Health Care System and Stanford University.
Status: Not yet recruiting
Start date: 2023-09-01
Phase II
Open
30 participants
Interventional
This double-blind, single-ascending dose trial (n=48) will assess the safety and tolerability of single ascending doses of orally administered Lucid-201 in healthy participants and patients with symptoms of depression on stable doses of SSRI or SNRI medications.
Status: Not yet recruiting
Start date: 2023-03-15
Phase I
Blinded
48 participants
Interventional
This open-label trial (n=10) will examine low-dose psilocybin as a safe treatment alternative for Fragile X Syndrome (FXS), aiming to improve markers of cognition, communication, mood, behaviour, neuroinflammation, serotonin levels in exosomes, and neuroplasticity.
Status: Recruiting
Start date: 2023-03-28
Phase II
Open
10 participants
Interventional
This clinical trial (n=16) aims to compare the pharmacokinetic and pharmacodynamic profiles of DMT and Harmine and their safety and tolerability through six study days with varying doses. Participants will be closely monitored for adverse events and receive continuous psychological support in a controlled environment.
Status: Not yet recruiting
Start date: 2023-05-01
Phase I
Blinded
16 participants
Interventional
This Phase III trial (n=252) investigated the effect of esketamine (58-84mg, 8x) on treatment-resistant depression (TRD). Ultimately the trial didn't find significant results at 28 days.
Status: Completed
Start date: 2018-02-15
Phase III
Blinded
252 participants
Interventional
This randomized, double-blind, single-site phase II trial (n=40) will investigate MDMA-assisted therapy's safety and preliminary efficacy compared with low-dose d-amphetamine-assisted therapy on the severity of PTSD symptoms in veterans with at least moderate PTSD severity.
Status: Not yet recruiting
Start date: 2023-10-01
Phase II
Blinded
40 participants
Interventional
This double-blind, placebo-controlled trial (n=40) aims to investigate the potential neurophysiological synergy effects between mindfulness meditation and psychedelics, particularly Ayahuasca, on experienced meditators.
Status: Recruiting
Start date: 2023-02-20
Phase I
Blinded
40 participants
Interventional
This open-label trial (n=20) aims to investigate the tolerability of ± 3,4-methylenedioxymethamphetamine (MDMA) in patients with schizophrenia. Impaired social motivation is a negative symptom of schizophrenia that has no effective treatment, and MDMA has shown promise in increasing social motivation and bonding in healthy individuals and other psychiatric conditions such as PTSD.
Status: Not yet recruiting
Start date: 2023-03-15
Phase I
Open
20 participants
Interventional
This trial (n=64) aims to investigate the safety and serum pharmacokinetics of 5-MeO-DMT in healthy volunteers. The study design is a double-blind, placebo-controlled, randomized design with single, injected doses of GH002 and an open-label, non-randomized study design with intra-subject dose-escalation of GH002.
Status: Planned
Start date: 2023-03-01
Phase I
Blinded
64 participants
Interventional
This trial (n=17) aimed to assess the abuse potential, subjective and physiological effects, pharmacokinetic parameters, and metabolism of methylone (200mg), a synthetic cathinone popularized as an alternative to illegal psychostimulants such as MDMA (100mg) and mephedrone.
Status: Completed
Start date: 2021-12-01
Phase I
Open
17 participants
Interventional
This open-label trial (n=12) will test repeated doses of psilocybin (first 10mg, then 3x 25mg; at least 7 days apart) and employ MRI scans to discover reliable brand and body reactions during the psychedelic experience. Specific to this study is that every 100 seconds participants will be asked about their rating (valence) of the experience.
Status: Not yet recruiting
Start date: 2023-02-01
Open
12 participants
Interventional
This double-blind, placebo-controlled trial (n=54) will administer 5-MeO-DMT intramuscular (IM) in varying doses from placebo to 16mg. Half of the cohorts (each with 5 getting 5-MeO, 1 placebo) will receive multiples doses (e.g. 2.5mg followed 3 hours later by 4.5mg). The trial will provide valuable data on the pharmacokinetics and safety of 5-MeO-DMT in humans.
Status: Recruiting
Start date: 2022-12-27
Phase I
Blinded
54 participants
Interventional
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study) (DMT BDR)
This open-label trial (n=36) will test a variety of mixed (or escalation) doses of DMT (5-25mg) in healthy subjects. The study is unique in testing many different dosages within the same subject (versus between groups).
Status: Not yet recruiting
Start date: 2023-03-15
Phase I
Open
36 participants
Interventional
Awakn Life Sciences has announced a Phase III trial to explore the effects of ketamine-assisted therapy in the treatment of alcohol use disorder (AUD).
Status: Planned
Start date: 2023-05-01
Phase III
Blinded
280 participants
Interventional
This trial (n=20) investigates the effects of psilocybin (18.2mg/70kg) on several brain measures and sleep quality.
Status: Completed
Start date: 2014-06-18
Phase I
Blinded
20 participants
Interventional
This trial (n=60) investigated the effect of MDMA (75mg) on the formation of memories. This was tested by simulating a crime (virtual reality). The trial found no significant effect of heightened vulnerability to external suggestions from MDMA.
Status: Completed
Start date: 2018-09-12
Phase I
Blinded
60 participants
Interventional
This neuroimaging trial (n=24) investigates the effects of one high dose of psilocybin (25mg) in those with depression. It specifically investigates the synaptic density (synapses are the connections between brain cells; neurons). The aim is to assess the relationship between the antidepressant and neurotrophic (growth within brain) effects of psilocybin.
Status: Not yet recruiting
Start date: 2023-01-01
Phase II
Open
24 participants
Interventional
This small open-label trial (n=8) will test the safety of two doses of the ayahuasca brew containing DMT (1.0mg to 1.4mg/kg). The trial is sponsored by Psychae and is done in collaboration with St. Vincent's Hospital in Melbourne Australia.
Status: Not yet recruiting
Start date: 2022-11-05
Phase I
Open
8 participants
Interventional
This open-label trial will assess the bioavailability of COMP360 (psilocybin) in healthy volunteers (n=14). The trial will assess the effects of both 5 and 25 mg doses of COMP360.
Status: Recruiting
Start date: 2022-06-16
Phase I
Open
14 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
